Glass House Brands has secured GACP certification for its Casitas and Padaro greenhouse farms, a regulatory milestone that pushes the California cultivator closer to supplying medical cannabis markets outside the United States. Perry Johnson Registrars Food Safety Inc. (PJRFSI) granted the certification on Oct. 11, 2026, confirming that both facilities meet the Good Agricultural and Collection Practice standard required by many international medical cannabis programs.
That distinction matters because GACP isn't a domestic adult-use benchmark. It's the same quality framework used across pharmaceutical-grade botanical supply chains in Europe, and it's the entry ticket for any cultivator hoping to sell into regulated medical markets abroad.
Why GACP Certification Carries Weight
Most U.S. cannabis compliance work centers on state-level seed-to-sale tracking, lab testing, and packaging rules built for domestic adult-use and medical retail. GACP operates on a different axis entirely - it's an international standard focused on cultivation hygiene, process documentation, and agricultural traceability, the kind of rigor pharmaceutical ingredient suppliers are already used to. For a cannabis operator, earning it means opening greenhouse operations to third-party audit against criteria that have nothing to do with state METRC reporting and everything to do with meeting import requirements in countries that treat cannabis as a regulated pharmaceutical input.
Combined, Casitas and Padaro span more than half a million square feet of greenhouse cultivation, which Glass House describes as among the largest GACP-certified footprint in the country. Scale alone doesn't guarantee certification, though; the audit process evaluates standard operating procedures, record-keeping, and facility controls at a granularity most adult-use cultivators never have to document.
The Export Question Is Still Unresolved
Here's the catch, and it's a significant one: certification doesn't equal a shipping lane. Federal cannabis prohibition still blocks export from the U.S. in most circumstances, and Glass House is explicit that it can only supply foreign medical markets once U.S. federal law and the destination country's import rules both permit it. The company says it continues to work with state and federal agencies toward that outcome, alongside ongoing conversations with domestic and international partners - but no timeline is attached.
In practice, this puts Glass House in a position shared by a handful of other large-scale U.S. cultivators: regulatory-ready on paper, legally boxed in by federal status. Markets like Germany, the U.K., and Switzerland require GACP-compliant supply chains and represent exactly the kind of medical demand that could expand total addressable market for a company already producing at scale. Whether that translates into actual trade volume depends on federal movement that remains outside any single operator's control.
What It Signals for Multi-State Operators
For other MSOs watching from the sidelines, the move is less about one company's greenhouse footprint and more about positioning. International medical markets generally support wholesale pricing well above what's typical in saturated U.S. adult-use markets, where oversupply and compressed margins have squeezed cultivators for seasons. A cultivator holding GACP certification is essentially building optionality - a bet that federal or international policy eventually opens a door that pays off in access to higher-margin medical channels.
That optionality isn't free. Maintaining GACP compliance means ongoing audit cycles, documentation overhead, and cultivation practices calibrated to a stricter standard than most U.S. regulators currently demand. For operators evaluating whether to pursue similar certification, the calculus comes down to a straightforward question: is the cost of building pharmaceutical-grade compliance infrastructure justified by a market that may or may not become accessible on any predictable schedule? Glass House is wagering yes. Not every cultivator has the balance sheet, or the greenhouse scale, to make the same bet.
